LEON-nanodrugs GmbH, a disrupting enabler of nanotechnology for the pharmaceutical industry, established its own lab facilities at the Start-Up Center for Biotechnology (IZB) in Munich. The new R&D capacities set the stage for completion of product development for LEON’s manufacturing devices and will afterwards be used to showcase the devices and provide process development services to clients using LEON’s equipment.

LEON’s product platform is built on its FR-JET Technology that enables a huge efficiency increase in the formulation process of active ingredients into nanodrug carriers such as lipid nanoparticles (LNPs).

LEON’s devices, NANOme and NANOus, are designed for aseptic processing, GMP-compliance and quick scale-up. NANOme is optimized for small-scale individual patient and clinical trial-size production. NANOus is a fully automated, aseptic device enabling the LNP-encapsulation of APIs from medium- to large-scale with high throughput using process analytical technology (PAT).

Setu Kasera, head of science and engineering, said: “We are truly excited about moving into the IZB. As one of the key biotech hubs in Germany, the IZB provides not only lab facilities, but also an unparalleled environment to foster innovation and growth. The local proximity to biotech start-ups, academia, VCs and big pharma creates an ecosystem that facilitates networking in- and outside of your peer group, setting the stage for future cooperations and partnerships. “We are looking forward to using our new capacities to complete the development of our devices for the market, while we pursue and build on opportunities for collaborations by providing access to our devices and process development services.”